Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BH4 Responsiveness in PKU Prediction
NCT07255599Phase 1Active, not recruiting
- Sponsor
- Sohag University
- Start
- Sep 2025
- Primary completion
- Jan 2026
- Modality
- Allosteric Modulators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sapropterin in phenylketonuria (PKU), sponsored by Sohag University. Primary endpoint: Serum phenylalanine level at 48 hours. Started Sep 2025; status: active, not recruiting.
02
Drugs
sapropterin
03
Conditions
phenylketonuria (PKU)
Beyond the preview
Go deeper on NCT07255599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07255599.